Jubilant Pharmova Ltd - 530019 - Employees Stock Option Plan 2018
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Nomination, Remuneration and Compensation Committee (the 'Committee') of the Company has, at its meeting held today i.e. Friday, July 23, 2021, approved implementation of Employees Stock Option Plan 2018 and has granted stock options as mentioned in the disclosure
Earnings Call for Q1FY22 of Jubilant Pharmova
Conference Call with Jubilant Pharmova Management and Analysts on Q1FY22 Performance and Outlook. Listen to the full earnings transcript. Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of Jubilant Pharmova Limited ('JPM'), at its meeting held on July 23, 2021, has approved the demerger of the Active Pharmaceutical Ingredients (API) undertaking of Jubilant Generics Limited ('JGL' - a wholly owned subsidiary of the Company) and vesting of the same with JPM, on a going concern basis ('Proposed Demerger'), to be implemented through a scheme of arrangement between JGL and JPM and their respective shareholders and creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ('Proposed Scheme'). The details as required to be disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated September 9, 2015, are enclosed at 'Annexure A'. Kindly take the above information on record. Jubilant Pharmova Ltd - 530019 - Results For Quarter Ended June 30, 2021
In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2021 were approved by the Board of Directors of the Company at its meeting held today at 1:30 p.m. and concluded at 4.00 p.m. Pursuant to the applicable provisions of the Listing Regulations, we enclose the following: 1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2021; 2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter; and 3. Copies of the Press Release and Presentation. We request you to take the same on records. Jubilant Pharmova Ltd - 530019 - Shareholding for the Period Ended June 30, 2021
Jubilant Pharmova Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here Jubilant Pharmova Ltd - 530019 - Schedule Of Investor Conference Call For Jubilant Pharmova Limited - Unaudited Financial Results For The Quarter Ended June 30, 2021
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising a Conference Call on July 23, 2021 after submission of the financial results for the quarter ended June 30, 2021 to the Stock Exchanges. Details of the Conference Call are attached. Jubilant Pharmova Ltd - 530019 - Schedule Of Investor Conference Call For Jubilant Pharmova Limited - Unaudited Financial Results For The Quarter Ended June 30, 2021
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising a Conference Call on July 23, 2021 after submission of the financial results for the quarter ended June 30, 2021 to the Stock Exchanges. Details of the Conference Call are attached. Jubilant Pharmova Ltd - 530019 - Board Meeting Intimation for Intimation Of Board Meeting - July 23, 2021
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2021 ,inter alia, to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, July 23, 2021, to inter-alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2021. Jubilant Pharmova Ltd - 530019 - Announcement Under Regulation 30 - Updates
Dear Sirs, We enclose a communication pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. We request you to take the same on record. Jubilant Pharmova Ltd - 530019 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, we are enclosing a Confirmation Certificate for the quarter ended June 30, 2021 received from M/s Alankit Assignments Limited, Registrar and Share Transfer Agent of the Company.